プロの翻訳者、企業、ウェブページから自由に利用できる翻訳レポジトリまで。
daclizumab.
appreciable daclizumab serum levels
最終更新: 2011-10-23
使用頻度: 1
品質:
警告: このアラインメントは正しくない可能性があります。
間違っていると思う場合は削除してください。
substanţa activă este daclizumab.
the active substance is daclizumab.
最終更新: 2017-04-26
使用頻度: 3
品質:
substanţa activă a zinbryta este daclizumab.
the active substance in zinbryta is daclizumab.
最終更新: 2017-04-26
使用頻度: 1
品質:
daclizumab aparţine unui grup de medicamente numite imunosupresoare.
daclizumab belongs to a group of medicines called immunosuppressants.
最終更新: 2017-04-26
使用頻度: 3
品質:
daclizumab nu a fost studiat la pacienţii cu insuficienţă hepatică.
daclizumab has not been studied in patients with hepatic impairment.
最終更新: 2017-04-26
使用頻度: 1
品質:
zenapax 5 mg/ml concentrat pentru soluţie perfuzabilă daclizumab
zenapax 5 mg/ml concentrate for solution for infusion daclizumab
最終更新: 2017-04-26
使用頻度: 3
品質:
există date limitate privind utilizarea daclizumab la femeile gravide.
there are limited data from the use of daclizumab in pregnant women.
最終更新: 2017-04-26
使用頻度: 1
品質:
acesta conţine substanţa activă daclizumab (5 mg/ ml).
zenapax is a concentrate to be made up into a solution for infusion (drip lon active substance daclizumab (5 mg/ ml).
最終更新: 2011-10-23
使用頻度: 1
品質:
警告: このアラインメントは正しくない可能性があります。
間違っていると思う場合は削除してください。
daclizumab *.................. 5 mg pentru 1 ml concentrat pentru soluţie perfuzabilă.
uth daclizumab*………… 5 mg per 1 ml infusion
最終更新: 2011-10-23
使用頻度: 1
品質:
警告: このアラインメントは正しくない可能性があります。
間違っていると思う場合は削除してください。
t iza daclizumab *.................. 5 mg pentru un ml concentrat pentru soluţie perfuzabilă
daclizumab*………… 5 mg per 1 ml infusion
最終更新: 2011-10-23
使用頻度: 1
品質:
警告: このアラインメントは正しくない可能性があります。
間違っていると思う場合は削除してください。
menţinerea grefei la trei ani nu a fost semnificativ diferită între placebo şi daclizumab în ln
the three year patient survival rate was significantly different between placebo and daclizumab in the
最終更新: 2012-04-11
使用頻度: 2
品質:
un flacon a 5 ml conţine daclizumab * 25 mg (5 mg/ ml).
ed one vial of 5 ml contains 25 mg of daclizumab* (5 mg/ ml).
最終更新: 2011-10-23
使用頻度: 1
品質:
警告: このアラインメントは正しくない可能性があります。
間違っていると思う場合は削除してください。
la majoritatea pacienţilor dozele recomandate de daclizumab vor menţine concentraţii plasmatice suficiente pentru a satura receptorii pr
serum levels of 0.5 to 0.9 µg/ ml are needed to saturate the il-2 receptor and levels of 5-10 µg/ ml are needed to inhibit il-2 mediated biologic activity.
最終更新: 2011-10-23
使用頻度: 1
品質:
警告: このアラインメントは正しくない可能性があります。
間違っていると思う場合は削除してください。
fiecare stilou injector (pen) preumplut conţine daclizumab 150 mg în 1 ml soluţie injectabilă.
each pre-filled pen contains 150 mg of daclizumab in 1 ml solution for injection.
最終更新: 2017-04-26
使用頻度: 1
品質:
te 1 mg/ kg daclizumab si a rămas saturată pentru cel puţin, primele trei luni după transplant.
7 subunit of the il-2 receptor was saturated immediately after the first dose of 1.0 mg/ kg of daclizumab and remained saturated for at least the first three months post-transplant.
最終更新: 2011-10-23
使用頻度: 1
品質:
警告: このアラインメントは正しくない可能性があります。
間違っていると思う場合は削除してください。
este de aşteptat ca potenţialele reacţii adverse apărute peste acest nivel să fie concordante cu profilul de siguranţă pentru daclizumab la pacienţii cu sm.
potential adverse reactions beyond this level are expected to be consistent with the safety profile for daclizumab in ms patients.
最終更新: 2017-04-26
使用頻度: 1
品質:
fiecare seringă preumplută conţine daclizumab 150 mg în 1 ml fiecare stilou injector (pen) conţine daclizumab 150 mg în 1 ml
each pre-filled syringe contains 150 mg of daclizumab in 1 ml each pre-filled pen contains 150 mg of daclizumab in 1 ml
最終更新: 2017-04-26
使用頻度: 1
品質:
rata de supravieţuire a pacienţilor la trei ani a fost semnificativ diferită între placebo şi daclizumab în studiul cu terapie imunosupresoare dublă (88% ina
ra double immunosuppressant trial (88% vs.
最終更新: 2011-10-23
使用頻度: 1
品質:
警告: このアラインメントは正しくない可能性があります。
間違っていると思う場合は削除してください。
daclizumab este produs în cadrul unei linii de celule de la mamifere (ns0) cu ajutorul tehnologiei adn-ului recombinant.
daclizumab is produced in a mammalian cell line (ns0) by recombinant dna technology.
最終更新: 2017-04-26
使用頻度: 1
品質:
un studiu non-clinic de toxicitate reproductivă cu daclizumab a demonstrat o creştere a riscului de pierdere prematură de sarcină comparativ cu placebo, la maimuţele cynomolgus.
a non-clinical reproduction toxicity study with daclizumab has shown an increased risk of early prenatal loss in cynomolgus monkeys compared to placebo.
最終更新: 2017-04-26
使用頻度: 1
品質: